New combo aims to control resistant liver cancer
Disease control
Terminated
This study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with liver cancer that no longer responds to lenvatinib alone. Only 5 people were enrolled before the study was stopped early. The goal was to see if the combination…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC